PROTACs: Promising approach for anticancer therapy
Cancer Letters · 2023-03 · 556 · 216065
DOI: 10.1016/j.canlet.2023.216065 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2023-03. Verfasst von Simran Deep Kaur und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Shoolini University of Biotechnology and Management Sciences, Solan, 173229, India. Hauptthemen laut MEDLINE: Neoplasms, Proteasome Endopeptidase Complex, Proteolysis, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
Proteolysis-targeting chimeras (PROTACs) are being developed as an effective method for degrading cancer-related proteins by modifying the endogenous ubiquitin-proteasome system. To investigate the dynamics between an E3 ligase and target protein, researchers have developed a wide variety of bifunctional PROTACs by combining small molecule ligands. These PROTACs employ numerous ligands, some of which are reversible, some of which are irreversible, some attach to orthosteric sites, while others bind to allosteric sites. Some are agonists, while others are antagonists, and the target protein may be activated in either a positive or negative manner. A variety of targeted ligand approaches can be used to enhance PROTAC properties, including tumor selectivity and drug delivery, and to overcome drug resistance. The processes and behaviors of small molecule-based PROTACs and targeted proteolysis approaches as anticancer therapeutic molecules have been introduced in this mini-review.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Shoolini University of Biotechnology and Management Sciences, Solan, 173229, India.
- Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, 143005, India.
- School of Pharmaceutical Sciences, Shoolini University of Biotechnology and Management Sciences, Solan, 173229, India. Electronic address: deepakpharmatech@gmail.com.
Zitieren
APA
Kaur, S. D., Bedi, N., Kumar, D., & Kapoor, D. N. (2023). PROTACs: Promising approach for anticancer therapy. Cancer Letters, 556, 216065. https://doi.org/10.1016/j.canlet.2023.216065
Vancouver
Kaur SD, Bedi N, Kumar D, Kapoor DN. PROTACs: Promising approach for anticancer therapy. Cancer Letters. 2023;556:216065. doi:10.1016/j.canlet.2023.216065
BibTeX
@article{Kaur2023,
author = {Kaur, Simran Deep and Bedi, Neena and Kumar, Deepak and Kapoor, Deepak N},
title = {PROTACs: Promising approach for anticancer therapy},
journal = {Cancer Letters},
year = {2023},
volume = {556},
pages = {216065},
doi = {10.1016/j.canlet.2023.216065}
}
EUVIMED